4//SEC Filing
Perlmutter Nathan M 4
Accession 0001493152-23-006949
CIK 0001712762other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 7:50 PM ET
Size
42.7 KB
Accession
0001493152-23-006949
Insider Transaction Report
Form 4
Perlmutter Nathan M
10% Owner
Transactions
- Conversion
Common Stock, par value $0.007
2022-09-06$4.20/sh+31,780$133,476→ 197,869 total - Conversion
Common Stock, par value $0.007
2022-09-06$4.20/sh+87,851$368,974→ 285,720 total - Conversion
Common Stock, par value $0.007
2022-09-06$4.20/sh+27,378$114,988→ 313,098 total - Conversion
Common Stock, par value $0.007
2022-09-06$6.75/sh+14,811$99,974→ 327,909 total - Conversion
Secured Convertible Promissory Note
2022-09-06→ 0 totalExercise: $4.20From: 2022-09-06Exp: 2022-10-31→ Common Stock (31,780 underlying) - Conversion
Secured Convertible Promissory Note
2022-09-06→ 0 totalExercise: $4.20From: 2022-09-06Exp: 2022-10-31→ Common Stock (87,851 underlying) - Conversion
Unsecured Convertible Promissory Note
2022-09-06→ 0 totalExercise: $4.20From: 2022-09-06Exp: 2022-10-31→ Common Stock (27,378 underlying) - Conversion
Series A Convertible Preferred Stock
2022-09-06−103,682→ 0 totalExercise: $6.75→ Common Stock (14,811 underlying) - Award
Warrant (right to buy)
2022-09-06+24,602→ 24,602 totalExercise: $6.13From: 2022-09-06Exp: 2026-08-25→ Common Stock (24,602 underlying) - Award
Warrant (right to buy)
2022-09-06+71,428→ 71,428 totalExercise: $6.13From: 2022-09-06Exp: 2026-11-22→ Common Stock (71,428 underlying) - Award
Warrant (right to buy)
2022-09-06+23,809→ 23,809 totalExercise: $6.13From: 2022-09-06Exp: 2026-12-02→ Common Stock (23,809 underlying) - Award
Warrants (right to buy)
2022-07-20+47,935→ 47,935 totalExercise: $5.25From: 2022-07-20Exp: 2027-07-20→ Common Stock (47,935 underlying)
Footnotes (9)
- [F1]The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
- [F2]In connection with the IPO closing on September 6, 2022, the $133,476.00 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a "Note"), dated January 14, 2019, automatically converted into 31,780 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
- [F3]In connection with the IPO closing on September 6, 2022, the $368,975.34 of outstanding principal and accrued but unpaid interest of this secured Note, dated October 23, 2019, automatically converted into 87,851 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
- [F4]In connection with the IPO closing on September 6, 2022, the $114,991.78 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 22, 2020, automatically converted into 27,378 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).
- [F5]In connection with the IPO closing on September 6, 2022, the 103,682 shares of Series A Convertible Preferred Stock owned by Mr. Perlmutter automatically converted at the then-effective 1 for 7 conversion rate (as adjusted for the Issuer's 1-for-7 reverse stock split) into 14,811 fully paid and nonassessable shares of Common Stock. The Series A Convertible Preferred Stock had no expiration date.
- [F6]Represents a right to purchase 24,602 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Perlmutter on August 25, 2021 as consideration for funds he paid to the Issuer for certain of his Notes.
- [F7]Represents a right to purchase 71,428 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Perlmutter on November 22, 2021 as consideration for funds he paid to the Issuer for certain of his Notes.
- [F8]Represents a right to purchase 23,809 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Perlmutter on December 9, 2021 as consideration for his agreement to amend his unsecured Note to extend its maturity date to May 31, 2022.
- [F9]Represents a right to purchase an aggregate of 47,935 shares of Common Stock underlying three warrants at an exercise price of $5.25 per share. The warrants were issued to Mr. Perlmutter on July 20, 2022 as consideration for his agreement to amend his unsecured Note to extend its maturity date to October 31, 2022.
Documents
Issuer
bioAffinity Technologies, Inc.
CIK 0001712762
Entity typeother
Related Parties
1- filerCIK 0001947867
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 7:50 PM ET
- Size
- 42.7 KB